Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events
The advent of immune checkpoint inhibitors (ICIs) has significantly transformed cancer treatment outcomes. However, these therapies can induce immune-related adverse events (irAEs) that may affect any organ system, sometimes requiring specialized expertise. As ICIs are increasingly used across vario...
Saved in:
| Main Authors: | Khashayar Esfahani, John Walker, Kevin Bambury, Eoin O’Carroll, Stephanie Snow |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
by: Chen Li, et al.
Published: (2025-05-01) -
A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
by: Le Xu, et al.
Published: (2025-12-01) -
Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors
by: Ping Luo, et al.
Published: (2025-12-01) -
Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
by: Mengyuan Liu, et al.
Published: (2025-03-01) -
Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
by: Mengyuan Liu, et al.
Published: (2025-05-01)